Evidence map›Paper›PMID 40271711›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Malignant Hepatoblast-Like Cells Sustain Stemness via IGF2-Dependent Cholesterol Accumulation in Hepatoblastoma.

Miao Ding, Siwei Mao, Han Wu, Sijia Fang, Ni Zhen, Tianshu Chen, Jiabei Zhu, Xiaochen Tang, Xiaoyang Wang, Fenyong Sun and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Miao DingDepartment of Clinical Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.ORCID https://orcid.org/0000-0001-8674-2731
Siwei MaoDepartment of Clinical Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.
Han WuDepartment of Clinical Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.
Sijia FangDepartment of Clinical Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.
Ni ZhenDepartment of Clinical Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.
Tianshu ChenDepartment of Clinical Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.
Jiabei ZhuDepartment of Clinical Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.
Xiaochen TangDepartment of Clinical Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.
Xiaoyang WangDepartment of Clinical Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.
Fenyong SunDepartment Laboratory Medicine, Shanghai Tenth People's Hospital of Tongji University, Shanghai, 200072, P. R. China.
Guoqing ZhuDepartment of Clinical Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.
Qiuhui PanDepartment of Clinical Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.ORCID https://orcid.org/0000-0001-7386-2590
Ji MaDepartment of Clinical Laboratory, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.ORCID https://orcid.org/0009-0005-4417-1949

Funding

Fundamental Research Funds for the Central Universities YG2022QN092Key project of Shanghai "Science and Technology Innovation Action Plan" 21JC1406602Key project of Shanghai "Science and Technology Innovation Action Plan" 22JC1402300Leading Talents in Health Care of Shanghai Municipal Health Commission 2022LJ020Medical Innovation Research Special Project of Scientific and Technological Innovation Action Plan of Shanghai 22Y11908200National Natural Science Foundation of China 82072375National Natural Science Foundation of China 82172357National Natural Science Foundation of China 82202621National Natural Science Foundation of China 82293662Shanghai Education Development Foundation and Shanghai Municipal Education Commission 22CGA18Shanghai Key Laboratory of Clinical Molecular Diagnostics for Pediatrics 20dz2260900Shanghai Municipal Health Commission 20214Y0153
6 · The paper itself

Abstract

Hepatoblastoma, the most aggressive childhood liver tumor, poses significant challenges due to limited knowledge of its pathogenesis, particularly in poorly differentiated advanced tumors where the prognosis is dismal. Single-cell sequencing provides an in-depth exploration at the single-cell level and offers a deep understanding of tumor heterogeneity. Herein, single-cell transcriptomics analysis is used to identify a unique malignant-hepatoblast (HB)-like cell subpopulation as the possible origin of poorly differentiated hepatoblastoma. These cells are associated with an unfavorable clinical prognosis in hepatoblastoma patients. The malignant-HB-like cell subpopulation generated insulin-like growth factor 2 (IGF2) to sustain stem-like features by promoting abnormal cholesterol accumulation via SREBF2. IGF2 also stimulated fibroblast 2 to secrete collagen 1, intensifying tumor malignancy via the collagen 1/integrin α1 signaling pathway. This suggests that targeting malignant HB-like cells by inhibiting IGF2-induced pathways can lead to promising treatments for hepatoblastoma. Additionally, serum IGF2 levels may serve as a diagnostic biomarker for advanced hepatoblastoma. In summary, these findings provide valuable insight into the genesis and malignancy of hepatoblastoma and a foundation for more effective diagnostic tools and therapeutic strategies for this challenging disease.

Indexed as

CholesterolHepatoblastomaInsulin-Like Growth Factor IILiver NeoplasmsNeoplastic Stem CellsCell Line, TumorHumansMaleCholesterolIGF2 protein, humanInsulin-Like Growth Factor IIcholesterolcollagen 1fibroblastIGF2malignant hepatoblast‐like cellsSREBF2stemness

Identifiers

PMID40271711
PMCPMC12120738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.